Baltic Post-Marketing Study of Pegilated Interferon Α-2a 40 KD Efficacy and Safety in Patients With HBeAg–Positive and HBeAg – Negative Chronic Hepatitis B

Virology & Mycology
doi 10.4172/2161-0517.1000108
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group